Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy

Science Translational Medicine

Volumn 6, Issue 237, 2014, Pages

  Highfill, Steven L ^a   Cui, Yongzhi ^a   Giles, Amber J ^a   Smith, Jillian P ^a   Zhang, Hua ^a   Morse, Elizabeth ^a   Kaplan, Rosandra N ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CXCR2 LIGAND; INTERLEUKIN 8; LIGAND; LYSINE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CELL EXPANSION; CELL MIGRATION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RHABDOMYOSARCOMA; SUPPRESSOR CELL; THERAPY DELAY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ANTIGENS, CD274; ANTIGENS, LY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHEMOKINE CXCL1; CHEMOTAXIS; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, INTERLEUKIN-8B; RHABDOMYOSARCOMA; TIME FACTORS; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84901334642     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007974     Document Type: Article

References (48)

1. R. J. Greenwald, G. J. Freeman, A. H. Sharpe, The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005).
2. G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, H. F. Horton, L. Fouser, L. Carter, V. Ling, M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, T. Honjo, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
3. M. E. Keir, S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, A. H. Sharpe, Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883-895 (2006).
4. H. Nishimura, T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, A. Mizoguchi, H. Hiai, N. Minato, T. Honjo, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
5. Y. Ishida, Y. Agata, K. Shibahara, T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992).
6. H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis, L. Chen, Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
7. D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
8. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, N. Minato, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99, 12293-12297 (2002).
9. J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, T. Honjo, S. Fujii, Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 3360-3365 (2007).
10. R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong, W. S. Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, L. Chen, H. Zincke, M. L. Blute, S. E. Strome, B. C. Leibovich, E. D. Kwon, Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 101, 17174-17179 (2004).
11. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
12. J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. Gupta, J. M. Wigginton, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
13. D. I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
14. + myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72, 876-886 (2012).
15. J. L. Meadors, Y. Cui,Q. R. Chen, Y. K. Song, J. Khan, G. Merlino,M. Tsokos, R. J. Orentas, C. L. Mackall, Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr. Blood Cancer 57, 921-929 (2011).
16. B. J. Weigel, D. A. Rodeberg, A. M. Krieg, B. R. Blazar, CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9, 3105-3114 (2003).
17. J. I. Youn, S. Nagaraj, M. Collazo, D. I. Gabrilovich, Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
18. P. C. Rodriguez, A. H. Zea, K. S. Culotta, J. Zabaleta, J. B. Ochoa, A. C. Ochoa, Regulation of T cell receptor CD3ξ chain expression by L-arginine. J. Biol. Chem. 277, 21123-21129 (2002).
19. J. Reutershan, CXCR2 - The receptor to hit? Drug News Perspect. 19, 615-623 (2006).
20. F. S. Hodi, S. J. O' Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
21. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Webber, C. Garbe, C. Lebbe, J. F. Baurain, A. Testori, J. J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. H. Miller Jr., P. Gascon, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, T. T. Chen, R. Humphrey, A. Hoos, J. D.Wolchok, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
22. J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
23. P. C. Rodriguez, M. S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra, A. C. Ochoa, Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560 (2009).
24. P. Serafini, I. Borrello, V. Bronte, Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65 (2006).
25. K. Movahedi, M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, J. A. Van Ginderachter, Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244 (2008).
26. L. Dolcetti, E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, M. Geilich, G. Winkels, E. Traggiai, A. Casati, F. Grassi, V. Bronte, Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40, 22-35 (2010).
27. N. Nausch, I. E. Galani, E. Schlecker, A. Cerwenka, Mononuclear myeloid-derived "suppressor"cells express RAE-1 and activate natural killer cells. Blood 112, 4080-4089 (2008).
28. S. K. Maenhout, S. Van Lint, P. U. Emeagi, K. Thielemans, J. L. Aerts, Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int. J. Cancer 134, 1077-1090 (2014).
29. B. Molon, S. Ugel, F. Del Pozzo, C. Soldani, S. Zilio, D. Avella, A. De Palma, P. Mauri, A. Monegal, M. Rescigno, B. Savino, P. Colombo, N. Jonjic, S. Pecanic, L. Lazzarato, R. Fruttero, A. Gasco, V. Bronte, A. Viola, Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208, 1949-1962 (2011).
30. A. Rot, U. H. von Andrian, Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928 (2004).
31. X. Fan, A. C. Patera, A. Pong-Kennedy, G. Deno, W. Gonsiorek, D. J. Manfra, G. Vassileva, M. Zeng, C. Jackson, L. Sullivan, W. Sharif-Rodriguez, G. Opdenakker, J. Van Damme, J. A. Hedrick, D. Lundell, S. A. Lira, R. W. Hipkin, Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J. Biol. Chem. 282, 11658-11666 (2007).
32. T. Kapanadze, J. Gamrekelashvili, C. Ma, C. Chan, F. Zhao, S. Hewitt, L. Zender, V. Kapoor, D. W. Felsher, M. P. Manns, F. Korangy, T. F. Greten, Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 59, 1007-1013 (2013).
33. L. Yang, J. Huang, X. Ren, A. E. Gorska, A. Chytil, M. Aakre, D. P. Carbone, L. M. Matrisian, A. Richmond, P. C. Lin, H. L. Moses, Abrogation of TGFb signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (2008).
34. H. Katoh, D. Wang, T. Daikoku, H. Sun, S. K. Dey, R. N. Dubois, CXCR2-expressing myeloidderived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24, 631-644 (2013).
35. S. Trellakis, K. Bruderek, J. Hütte, M. Elian, T. K. Hoffmann, S. Lang, S. Brandau, Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 19, 328-336 (2013).
36. A. C. Ochoa, A. H. Zea, C. Hernandez, P. C. Rodriguez, Arginase, prostaglandins, and myeloidderived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13, 721s-726s (2007).
37. D. J. Waugh, C. Wilson, The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735-6741 (2008).
38. Y.Mizukami, W. S. Jo, E. M. Duerr, M. Gala, J. Li, X. Zhang, M. A. Zimmer, O. Iliopoulos, L. R. Zukerberg, Y. Kohgo, M. P. Lynch, B. R. Rueda, D. C. Chung, Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat. Med. 11, 992-997 (2005).
39. A. Sparmann, D. Bar-Sagi, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458 (2004).
40. H. B. Jijon, A. Buret, C. L. Hirota, M. D. Hollenberg, P. L. Beck, The EGF receptor and HER2 participate in TNF-α-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells. Mediators Inflamm. 2012, 207398 (2012).
41. R. I. Fernando, M. D. Castillo, M. Litzinger, D. H. Hamilton, C. Palena, IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 71, 5296-5306 (2011).
42. I. H. Benoy, R. Salgado, P. Van Dam, K. Geboers, E. Van Marck, S. Scharpé, P. B. Vermeulen, L. Y. Dirix, Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10, 7157-7162 (2004).
43. H. Zhang, I. Maric, M. J. DiPrima, J. Khan, R. J. Orentas, R. N. Kaplan, C. L. Mackall, Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122, 1105-1113 (2013).
44. L. P. Seung, D. A. Rowley, P. Dubey, H. Schreiber, Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 92, 6254-6258 (1995).
45. M. K. Srivastava, L. Zhu, M. Harris-White, U. Kar, M. Huang, M. F. Johnson, J. M. Lee, D. Elashoff, R. Strieter, S. Dubinett, S. Sharma, Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLOS One 7, e40677 (2012).
46. K. M. Elias, A. Laurence, T. S. Davidson, G. Stephens, Y. Kanno, E. M. Shevach, J. J. O'Shea, Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111, 1013-1020 (2008).
47. B. D. Freeman, R. L. Danner, S. M. Banks, C. Natanson, Safeguarding patients in clinical trials with high mortality rates. Am. J. Respir. Crit. Care Med. 164, 190-192 (2001).
48. high cells in the mouse liver. Hepatology 32, 507-513 (2000)